| 规格或纯度 | 10mM in DMSO |
|---|---|
| 英文名称 | Ketorolac |
| 英文别名 | 5-?benzoyl-?2,?3-?dihydro-1H-?pyrrolizine-?1-?carboxylic acid,compd. with 2-?amino-?2-?(hydroxymethyl)?-?1,?3-?propanediol (1:1) |
| 生化机理 | Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively. |
| 储存温度 | -80℃储存 |
| 运输条件 | 超低温冰袋运输 |
| 产品介绍 |
Information Ketorolac is a non-selective COX inhibitor ofCOX-1andCOX-2withIC50of 1.23 μM and 3.50 μM, respectively. (R, S)-, (S)-, and (R)-Ketorolac inhibit both isoforms of COX in recombinant rat and human enzyme systems, and similar as inhibitors of rat COX (rCOX) and human COX (hCOX) under the conditions used. (R, S)-Ketorolac inhibits rat COX-1, rat COX-2, human COX-1 and human COX-2 with IC50 of 0.27 μM, 2.06 μM, 1.23 μM and 3.50 μM, respectively. The (S) enantiomer of Ketorolac with IC50 of 0.10 μM for rat COX-1 is approximately twice as potent as the racemate, whereas the (R)-enantiomer with IC50 of > 100 μM is virtually without activity. Ketorolac shows inhibition of eicosanoid formation in HEL cells (COX-1) and LPS-stimulated Mono Mac 6 cells (COX-2) with IC50 of 0.025 μM and 0.039 μM, respectively, but does not significantly inhibit NO accumulation in supernatants of LPS-stimulated RAW 264.7 cells up to 300 μM. Ketorolac significantly inhibits thymidine incorporation of human osteoblasts (hOBs) upon 24 hours treatment in a dose-dependent manner, and inhibits proliferation and arrests cell cycle at G0/G1 phase in hOBs. In?vivo (R, S)-Ketorolac is significantly more potent than indomethacin or diclofenac sodium in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats, with ID50 of 0.24, 0.29 and 0.08 mg/kg, respectively. Ketorolac produces significant inhibition of COX-1 activity and gastric PG synthesis with doses of ≥1 mg/kg inhibiting COX-1 activity by 95% and gastric PG synthesis by >88%. Ketorolac does not significantly affect COX-2 activity at doses of ≤3 mg/kg, but at doses of 10 and 30 mg/kg, Ketorolac produces significant inhibition of COX-2 activity by 75% and 91%, respectively. Ketorolac causes gastric damage in rats only at doses that inhibits both COX-1 and COX-2, or when given with a COX-2 inhibitor. cell?lines：Human glaucomatous trabecular meshwork (GTM3) cell line Concentrations：Dissolved in DMSO, final concentration ~0.1 mM Incubation?Time：24 hours Powder?Purity:≥99% |
| IC50 | COX-1 (human), IC50: 1.23 μM |
|---|
| Canonical SMILES | OC(=O)C1CC[N]2C1=CC=C2C(=O)C3=CC=CC=C3 |
|---|---|
| 分子量 | 255.27 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 41 mg/mL (196.87 mM); ? ? |
|---|
首页
400-620-6333
危险品化学品经营许可证（带存储）